1 134

Cited 29 times in

Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy

Authors
 Se-Hoon Lee  ;  Yung-Jue Bang  ;  Paul Mainwaring  ;  Christina Ng  ;  John W-C Chang  ;  Philip Kwong  ;  Rubi K Li  ;  Virote Sriuranpong  ;  Chee-Keong Toh  ;  Jinyu Yuan  ;  Susan Pitman Lowenthal  ;  Hyun C Chung 
Citation
 ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol.10(3) : 237-245, 2014 
Journal Title
 ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 
ISSN
 1743-7555 
Issue Date
2014
MeSH
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/administration & dosage* ; Antineoplastic Agents/adverse effects ; Asian Continental Ancestry Group ; Carcinoma, Renal Cell/drug therapy* ; Carcinoma, Renal Cell/ethnology ; Drug Administration Schedule ; Female ; Humans ; Indoles/administration & dosage* ; Indoles/adverse effects ; Kidney Neoplasms/drug therapy* ; Kidney Neoplasms/ethnology ; Male ; Middle Aged ; Prospective Studies ; Pyrroles/administration & dosage* ; Pyrroles/adverse effects ; Treatment Outcome ; Young Adult
Keywords
Asian ; metastatic renal cell carcinoma ; sunitinib
Abstract
AIMS: We evaluated and compared the safety and efficacy of sunitinib in Asian and non-Asian patients with metastatic renal cell carcinoma enrolled in a previously reported global expanded access program. METHODS: Previously treated and treatment-naïve patients received open-label sunitinib at a starting dose of 50 mg/day for 4 weeks, followed by 2 weeks off treatment, in repeated 6-week cycles. Safety was assessed regularly, tumor measurements were performed per local practice, and survival data collected where possible. RESULTS: Data were available for 212 Asian patients from Asian sites (Asian-A), 113 Asian patients from non-Asian sites (Asian-O) and 4046 non-Asian patients. The most common grade 3/4 treatment-related adverse events were neutropenia, thrombocytopenia, hand-foot syndrome, diarrhea, asthenia and fatigue. The incidence of many adverse events was greater in Asian-A than in Asian-O or non-Asian patients. Sunitinib efficacy was comparable between Asian and non-Asian patients, with an objective response rate of 18% versus 14%; median progression-free survival of 8.7 versus 10.9 months; and overall survival of 18.9 versus 18.4 months, respectively. CONCLUSIONS: Sunitinib demonstrated tolerable safety and similar efficacy in Asian and non-Asian patients. Geographic differences in the reported frequency of specific adverse events were noted across Asian patients.
Full Text
http://onlinelibrary.wiley.com/doi/10.1111/ajco.12163/abstract
DOI
10.1111/ajco.12163
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/99688
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse